Global Peripheral Vascular Disease (PVD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Peripheral Vascular Disease (PVD) treatment during 2019. Clinical development activities are being undertaken by more than 35 companies including 480 Biomedical Inc, Alucent Medical Inc, Anaeropharma Science Inc, AnGes MG Inc, AngioSoma Inc and others.
A Significant contribution to the Peripheral Vascular Disease (PVD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Peripheral Vascular Disease (PVD) pipeline included 35 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Peripheral Vascular Disease (PVD) condition and increased access to investments is encouraging growth of Peripheral Vascular Disease (PVD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Peripheral Vascular Disease (PVD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Peripheral Vascular Disease (PVD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Peripheral Vascular Disease (PVD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Peripheral Vascular Disease (PVD). Further, orphan drug status, fast track designation, grants awarded and other special status for Peripheral Vascular Disease (PVD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Peripheral Vascular Disease (PVD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Peripheral Vascular Disease (PVD) Pipeline candidates-
A Significant contribution to the Peripheral Vascular Disease (PVD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Peripheral Vascular Disease (PVD) pipeline included 35 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Peripheral Vascular Disease (PVD) condition and increased access to investments is encouraging growth of Peripheral Vascular Disease (PVD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Peripheral Vascular Disease (PVD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Peripheral Vascular Disease (PVD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Peripheral Vascular Disease (PVD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Peripheral Vascular Disease (PVD). Further, orphan drug status, fast track designation, grants awarded and other special status for Peripheral Vascular Disease (PVD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Peripheral Vascular Disease (PVD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Peripheral Vascular Disease (PVD) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Peripheral Vascular Disease (PVD) drugs
- Late phase: Phase 3 and in-approval Peripheral Vascular Disease (PVD) drugs
- Company overview
- Snapshot
- Peripheral Vascular Disease (PVD) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Peripheral Vascular Disease (PVD)- Disease Overview
2.2 Peripheral Vascular Disease (PVD)- Pipeline Snapshot
2.3 Peripheral Vascular Disease (PVD)- Pipeline Drugs by Phase
2.4 Peripheral Vascular Disease (PVD)- Pipeline Drugs by Company
2.5 Peripheral Vascular Disease (PVD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 480 Biomedical Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.2 Alucent Medical Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.3 Anaeropharma Science Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.4 AnGes MG Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.5 AngioSoma Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.6 Apceth Biopharma GmbH Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.7 Athera Biotechnologies AB Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.8 Athersys Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.9 Bayer AG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.10 Betagenon AB Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.11 BiogenCell Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.12 CardioVascular BioTherapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.13 Celularity Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.14 Exodos Life Sciences LP Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.15 Foresee Pharmaceuticals Co Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.16 G. Pohl-Boskamp GmbH & Co. KG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.17 Hemostemix Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.18 ID Pharma Co Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.19 Juventas Therapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.20 LipimetiX Development Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.21 MultiGene Vascular Systems (MGVS) Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.22 Nangiotx Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.23 Novartis AG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.24 Nuo Therapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.25 Pluristem Therapeutics Inc. Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.26 Proteon Therapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.27 Resverlogix Corporation Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.28 Reven Pharmaceuticals Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.29 RHEACELL GmbH & Co. KG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.30 SK Chemicals Co.,Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.31 Stemedica Cell Technologies Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.32 Symic Biomedical Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.33 VESSL Therapeutics Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.34 ViroMed Co Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.35 Yuyu Pharma Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Peripheral Vascular Disease (PVD)- Phase 1 Drug Details
4.2 Peripheral Vascular Disease (PVD)- Phase 1 Drug Overview
4.3 Peripheral Vascular Disease (PVD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Peripheral Vascular Disease (PVD)- Phase 2 Drug Details
5.2 Peripheral Vascular Disease (PVD)- Phase 2 Drug Overview
5.3 Peripheral Vascular Disease (PVD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Peripheral Vascular Disease (PVD)- Phase 3 Drug Details
6.2 Peripheral Vascular Disease (PVD)- Phase 3 Drug Overview
6.3 Peripheral Vascular Disease (PVD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Peripheral Vascular Disease (PVD)- Pre-clinical Phase Drug Details
7.2 Peripheral Vascular Disease (PVD)- Pre-clinical Phase Drug Overview
7.3 Peripheral Vascular Disease (PVD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Peripheral Vascular Disease (PVD)- Disease Overview
2.2 Peripheral Vascular Disease (PVD)- Pipeline Snapshot
2.3 Peripheral Vascular Disease (PVD)- Pipeline Drugs by Phase
2.4 Peripheral Vascular Disease (PVD)- Pipeline Drugs by Company
2.5 Peripheral Vascular Disease (PVD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 480 Biomedical Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.2 Alucent Medical Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.3 Anaeropharma Science Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.4 AnGes MG Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.5 AngioSoma Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.6 Apceth Biopharma GmbH Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.7 Athera Biotechnologies AB Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.8 Athersys Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.9 Bayer AG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.10 Betagenon AB Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.11 BiogenCell Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.12 CardioVascular BioTherapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.13 Celularity Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.14 Exodos Life Sciences LP Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.15 Foresee Pharmaceuticals Co Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.16 G. Pohl-Boskamp GmbH & Co. KG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.17 Hemostemix Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.18 ID Pharma Co Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.19 Juventas Therapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.20 LipimetiX Development Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.21 MultiGene Vascular Systems (MGVS) Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.22 Nangiotx Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.23 Novartis AG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.24 Nuo Therapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.25 Pluristem Therapeutics Inc. Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.26 Proteon Therapeutics Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.27 Resverlogix Corporation Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.28 Reven Pharmaceuticals Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.29 RHEACELL GmbH & Co. KG Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.30 SK Chemicals Co.,Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.31 Stemedica Cell Technologies Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.32 Symic Biomedical Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.33 VESSL Therapeutics Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.34 ViroMed Co Ltd Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
3.35 Yuyu Pharma Inc Peripheral Vascular Disease (PVD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Peripheral Vascular Disease (PVD)- Phase 1 Drug Details
4.2 Peripheral Vascular Disease (PVD)- Phase 1 Drug Overview
4.3 Peripheral Vascular Disease (PVD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Peripheral Vascular Disease (PVD)- Phase 2 Drug Details
5.2 Peripheral Vascular Disease (PVD)- Phase 2 Drug Overview
5.3 Peripheral Vascular Disease (PVD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Peripheral Vascular Disease (PVD)- Phase 3 Drug Details
6.2 Peripheral Vascular Disease (PVD)- Phase 3 Drug Overview
6.3 Peripheral Vascular Disease (PVD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Peripheral Vascular Disease (PVD)- Pre-clinical Phase Drug Details
7.2 Peripheral Vascular Disease (PVD)- Pre-clinical Phase Drug Overview
7.3 Peripheral Vascular Disease (PVD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
